Go To Global Site
Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis,  rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more. 

Spotlight Story

Advancing Our Mission to Cure Epilepsy

With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.

 

 

UCB U.S. News

Working Toward a More Equitable Future: Addressing Barriers in the Hispanic Epilepsy Community

Read More

FDA Approves Shelf Life Extension for NAYZILAM® (midazolam) Nasal Spray, CIV

Read More

Advancing Our Mission to Cure Epilepsy

Read More

Twitter Feed

For More Information